MY177001A - Phenothiazine compounds for treating mild cognitive impairment - Google Patents
Phenothiazine compounds for treating mild cognitive impairmentInfo
- Publication number
- MY177001A MY177001A MYPI20095255A MYPI20095255A MY177001A MY 177001 A MY177001 A MY 177001A MY PI20095255 A MYPI20095255 A MY PI20095255A MY PI20095255 A MYPI20095255 A MY PI20095255A MY 177001 A MY177001 A MY 177001A
- Authority
- MY
- Malaysia
- Prior art keywords
- cognitive impairment
- mild cognitive
- treating mild
- phenothiazine compounds
- phenothiazine
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 3
- 208000027061 mild cognitive impairment Diseases 0.000 title abstract 3
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 title 1
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical class C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94500607P | 2007-06-19 | 2007-06-19 | |
| PCT/GB2008/002066 WO2008155533A2 (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY177001A true MY177001A (en) | 2020-09-01 |
Family
ID=39943003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20095255A MY177001A (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9211294B2 (https=) |
| EP (1) | EP2167095B1 (https=) |
| JP (1) | JP5725605B2 (https=) |
| CN (1) | CN101820884B (https=) |
| AU (1) | AU2008265045B2 (https=) |
| BR (1) | BRPI0813670A2 (https=) |
| CA (1) | CA2690746C (https=) |
| DK (1) | DK2167095T3 (https=) |
| ES (1) | ES2739546T3 (https=) |
| HR (1) | HRP20191513T1 (https=) |
| HU (1) | HUE045460T2 (https=) |
| MY (1) | MY177001A (https=) |
| PL (1) | PL2167095T3 (https=) |
| PT (1) | PT2167095T (https=) |
| SI (1) | SI2167095T1 (https=) |
| WO (1) | WO2008155533A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| CA3027974C (en) * | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| CN102958525B (zh) | 2010-04-30 | 2017-05-24 | 普罗瑟塔抗病毒股份有限公司 | 抗病毒化合物 |
| EA025033B1 (ru) * | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| EP2951149B1 (en) * | 2013-01-30 | 2018-10-10 | Ecolab USA Inc. | Hydrogen sulfide scavengers |
| US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
| WO2016133995A1 (en) * | 2015-02-17 | 2016-08-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| KR102592614B1 (ko) * | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| DK3826639T3 (da) | 2018-07-26 | 2024-09-23 | Wista Lab Ltd | Optimeret dosering af diaminophenothiaziner i populationer |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| AU2024231880A1 (en) | 2023-03-03 | 2025-09-11 | Taurx Therapeutics Management Ltd. | Diaminophenothiazine for the treatment of microvascular brain disease disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2004087160A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| MY162640A (en) * | 2006-03-29 | 2017-06-30 | Wista Lab Ltd | Thioninium compounds and their use |
| PL2004155T3 (pl) | 2006-03-29 | 2018-08-31 | Wista Laboratories Ltd. | Inhibitory agregacji białek |
| DK3121169T3 (da) * | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
-
2008
- 2008-06-17 CN CN2008801031955A patent/CN101820884B/zh active Active
- 2008-06-17 SI SI200832080T patent/SI2167095T1/sl unknown
- 2008-06-17 PT PT08762390T patent/PT2167095T/pt unknown
- 2008-06-17 JP JP2010512761A patent/JP5725605B2/ja active Active
- 2008-06-17 WO PCT/GB2008/002066 patent/WO2008155533A2/en not_active Ceased
- 2008-06-17 ES ES08762390T patent/ES2739546T3/es active Active
- 2008-06-17 AU AU2008265045A patent/AU2008265045B2/en active Active
- 2008-06-17 DK DK08762390.6T patent/DK2167095T3/da active
- 2008-06-17 PL PL08762390T patent/PL2167095T3/pl unknown
- 2008-06-17 US US12/665,608 patent/US9211294B2/en active Active
- 2008-06-17 CA CA2690746A patent/CA2690746C/en active Active
- 2008-06-17 MY MYPI20095255A patent/MY177001A/en unknown
- 2008-06-17 EP EP08762390.6A patent/EP2167095B1/en active Active
- 2008-06-17 HR HRP20191513 patent/HRP20191513T1/hr unknown
- 2008-06-17 HU HUE08762390A patent/HUE045460T2/hu unknown
- 2008-06-17 BR BRPI0813670-0A2A patent/BRPI0813670A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US9211294B2 (en) | 2015-12-15 |
| BRPI0813670A2 (pt) | 2014-12-30 |
| ES2739546T3 (es) | 2020-01-31 |
| JP2010530403A (ja) | 2010-09-09 |
| EP2167095B1 (en) | 2019-05-29 |
| PT2167095T (pt) | 2019-08-06 |
| HRP20191513T1 (hr) | 2019-11-29 |
| PL2167095T3 (pl) | 2019-11-29 |
| US20100184752A1 (en) | 2010-07-22 |
| JP5725605B2 (ja) | 2015-05-27 |
| CA2690746C (en) | 2018-01-02 |
| WO2008155533A3 (en) | 2009-02-19 |
| CA2690746A1 (en) | 2008-12-24 |
| AU2008265045B2 (en) | 2014-02-27 |
| DK2167095T3 (da) | 2019-07-29 |
| EP2167095A2 (en) | 2010-03-31 |
| CN101820884A (zh) | 2010-09-01 |
| CN101820884B (zh) | 2013-08-28 |
| AU2008265045A1 (en) | 2008-12-24 |
| WO2008155533A2 (en) | 2008-12-24 |
| SI2167095T1 (sl) | 2019-09-30 |
| HUE045460T2 (hu) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY177001A (en) | Phenothiazine compounds for treating mild cognitive impairment | |
| NL301145I1 (https=) | ||
| MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| IL233634A0 (en) | Methods, compositions and kits for treating medical conditions | |
| MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
| MX2010004219A (es) | Agentes de enlace de cd19 y usos de los mismos. | |
| MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
| MX2009005725A (es) | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. | |
| MX394667B (es) | El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4- ciano-3-trifluorometll-fen|l)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ilideno]-tiourea. | |
| TW200716624A (en) | Compounds for modulating TRPV3 function | |
| TNSN08400A1 (en) | Organic compounds and their uses | |
| MX360301B (es) | Moleculas pequeñas que contienen boro como agentes antiinflamatorios. | |
| MY158325A (en) | Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection | |
| HUE059861T2 (hu) | N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra | |
| WO2010036395A3 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
| EP1924293A4 (en) | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I | |
| IL205562A0 (en) | Benzodiazepinone compounds useful in the treatment of skin conditions | |
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| MX2008011872A (es) | Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. | |
| MX2010002909A (es) | Metodo de tratamiento de pacientes de hepatitis c. | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| MY155340A (en) | Use of cathepsin c | |
| TW200716088A (en) | Formulations and methods for treating amyloidosis | |
| MX2009013214A (es) | Macrociclos y sus usos. |